Abbreviations, acronyms & symbols | ||||
---|---|---|---|---|
ADH | = Antidiuretic hormone | HLP | = Heart-lung pump | |
AKI | = Acute kidney injury | IL-18 | = Interleukin-18 | |
AKIN | = Acute Kidney Injury Network | KDIGO | = Kidney Disease Improving Global Outcomes | |
BMI | = Body mass index | LVAD | = Left ventricular assist device | |
CABG | = Coronary artery bypass grafting | MAP | = Mean arterial pressure | |
CAP | = Central arterial pressure | MPP | = Mean perfusion pressure | |
COPD | = Chronic obstructive pulmonary disease | NGAL | = Neutrophil gelatinase-associated lipocalin | |
CPB | = Cardiopulmonary bypass | PAP | = Pulmonary artery pressure | |
CSA-AKI | = Cardiac surgery-associated acute kidney injury | RIFLE | = Risk, Injury, Failure, Loss of function, and End-stage kidney disease | |
CVP | = Central venous pressure | RRT | = Renal replacement therapy | |
DO2 | = Oxygen delivery | SS | = Standard deviation values | |
DPP | = Diastolic perfusion pressure | |||
FFP | = Fresh frozen plasma |
Min-max | Median | Mean ± SS N% | |||
---|---|---|---|---|---|
Age | 24.0-84.0 | 60.5 | 64.52±9.32 | ||
Gender | Female | 29 | 29% | ||
Male | 71 | 71% | |||
Weight (kg) | 52-135 | 76.5 | 77.33±13.2 | ||
BMI (kg/m2) | 19.8-41.2 | 26.58 | 27.10±4.3 | ||
Diabetes mellitus | 29 | 29% | |||
Hypertension | 52 | 52% | |||
Asthma | 4 | 4% | |||
COPD | 4 | 4% | |||
Creatine level (> 1,2 mg/dl) | 12 | 12% |
AKI (+) | AKI (-) | P-value | Total | |||
---|---|---|---|---|---|---|
N=24 | N=76 | N=100 | ||||
Age | 65.76±7.7 | 60.58±2.64 | >0.05 | 100 | ||
Gender | Female | 4 | 25 | >0.05 | 29 | |
Male | 20 | 51 | >0.05 | 71 | ||
Weight (kg) | 76.25±2,25 | 77.7±1.5 | >0.05 | 100 | ||
BMI (kg/m2) | 26.11±0.11 | 27.4±0.5 | >0.05 | 100 | ||
Hypertension | Existing | 14 | 38 | >0.05 | 52 | |
None | 10 | 38 | 48 | |||
Diabetes mellitus | Existing | 8 | 21 | >0.05 | 29 | |
None | 16 | 55 | 71 | |||
Asthma | Existing | 0 | 4 | >0.05 | 4 | |
None | 24 | 72 | 96 | |||
COPD | Existing | 1 | 3 | >0.05 | 4 | |
None | 23 | 73 | 96 | |||
Creatine level (> 1,2 mg/dl) | Existing | 9 | 3 | <0.05* * Significant value. | 12 | |
None | 15 | 73 | 88 | |||
OPAQ** ** OPAQ is a contrast solution given to patients during angiography. duration (day) | 32±7.7 | 25.9±2.7 | <0.05 | 100 | ||
EuroSCORE | 3.3±0.4 | 3.1±0.15 | >0.05 | 100 | ||
Surgical planning | Elective | 19 | 65 | >0.05 | 84 | |
Emergent | 5 | 11 | 16 | |||
Surgery type | CABG | 13 | 37 | 50 | ||
Single valve replacement | 2 | 13 | 15 | |||
Double valve replacement | 2 | 5 | >0.05 | 7 | ||
CABG+valve replacement | 3 | 4 | 7 | |||
LVAD | 4 | 17 | 21 | |||
Extubation period (hour) | 24.7±6.2 | 10.4±1.8 | <0.05* * Significant value. | 100 | ||
Complication | Wound infection | 0 | 5 | 5 | ||
Atrial fibrillation | 1 | 0 | 1 | |||
Cardiac tamponade | 7 | 1 | <0.05* * Significant value. | 8 | ||
Pneumonia | 3 | 2 | 5 | |||
None | 13 | 68 | 81 |
MAP | CVP | PAP | Diastole-CVP | MAP-CVP | |
---|---|---|---|---|---|
Preinduction | 79.41±2.02 | ||||
Postintubation | 73.70±2.35 | 9.29±0.93 | 30.83±2.04 | 49.08±1.93 | 63±2.58 |
CPB inlet | 72±2.40 | 7.04±0.86 | 29.70±2.14 | 48.58±2.13 | 63.45±2.28 |
CPB separation | 71±3.17 | 8.62±0.78 | 29.33±1.68 | 47.16±3.71 | 60.91±3.07 |
End of surgery | 76.41±2.77 | 8.79±0.80 | 27.87±1.89 | 50.83±2.71 | 65.33±3.72 |
MAP | CVP | PAP | Diastole-CVP | MAP-CVP | |
---|---|---|---|---|---|
Preinduction | 78.42±1.27 | ||||
Postintubation | 73.53±1.73 | 9,18±0.46 | 26.47±1.07 | 49.80±1.34 | 66.42±1.65 |
CPB inlet | 74.96±1.45 | 7.18±0.41 | 25.98±0.94 | 51.85±1.07 | 69.30±1.48 |
CPB separation | 71.05±1.39 | 7.86±0.40 | 25.68±0.90 | 48.64±1.30 | 66.89±1.36 |
End of surgery | 74.89±1.14 | 8.17±0.36 | 25.11±0.88 | 50.06±1.14 | 65.92±1.09 |
Author's roles & responsibilities | |
---|---|
HM | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work |
EG | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; drafting the work or revising it critically for important intellectual content; final approval of the version to be published; agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved |
TAT | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work |
IOK | Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved |